top of page

Advancing Care with Innovative Sweat Sensor Technology with Leading Clinicians

October 4, 2023

https://www.businesswire.com/news/home/20231004100828/en/EnLiSense-CCM-To-Advance-IBD-Care-with-Innovative-Sweat-Sensor-Studies-Teams-Up-with-Leading-Clinicians

EnLiSense CCM, a pioneer in non-invasive, real-time inflammatory biomarker monitoring, announces the initiation of multiple groundbreaking clinical studies in collaboration with top-tier medical institutions to further the management of Chronic Diseases

DALLAS--(BUSINESS WIRE)--EnLiSense CCM, a pioneer in non-invasive, real-time inflammatory biomarker monitoring, announces the initiation of multiple groundbreaking clinical studies in collaboration with top-tier medical institutions to further the management of Inflammatory Bowel Disease (IBD). Building on the momentum from the previous venture funding by the Crohn's and Colitis Foundation, EnLiSense CCM is partnered with premier medical institutions like the University of Chicago, Mount Sinai, University of Glasgow, and University of Texas Dallas to develop a decision-support tool for physicians and patients.

“The initial validation data is indeed very encouraging. We are beginning to uncover unforeseen circadian rhythms and other insightful patterns which are crucial for understanding IBD dynamics. Although it's still early days, these findings are a promising step towards a future where real-time monitoring can significantly enhance disease management.”

Patients and clinicians are now actively being enrolled in these studies, marking a pivotal phase in EnLiSense's journey towards revolutionizing chronic disease management. EnLiSense invites individuals interested in participating to learn more and join us by visiting IBDwearable.com.


The IBD Aware system, a cornerstone of EnLiSense's innovative approach, continuously monitors key inflammatory biomarkers by gently resting on a patient’s skin sampling just nano-liters of passive sweat. This non-invasive, wearable technology empowers both clinicians and patients with real-time data, facilitating personalized, data-driven, proactive management of chronic diseases like IBD.


Dr. Sriram Muthukumar, CEO of EnLiSense CCM, reflects on the early findings, stating, "The initial validation data is indeed very encouraging. We are beginning to uncover unforeseen circadian rhythms and other insightful patterns which are crucial for understanding IBD dynamics. Although it's still early days, these findings are a promising step towards a future where real-time monitoring can significantly enhance disease management."


Dr. Shalini Prasad, Chief Scientific Officer at EnLiSense CCM, envisions a profound impact on patients with chronic diseases. She remarks, "Our technology is poised to transform lives by enabling patients to monitor their disease activity in real-time, from the comfort of their homes. This not only fosters a proactive and personalized approach to disease management but also bridges the geographical gap between patients and physicians, making quality care accessible irrespective of distance."


The IBD Aware system is engineered to monitor key IBD biomarkers including Calprotectin, Tumor Necrosis Factor alpha (TNF-α), C-Reactive Protein (CRP), and Interleukin-6 (IL6), providing a comprehensive view of IBD disease activity. Beyond these, EnLiSense is actively engaged in research to extend the monitoring capabilities to other significant biomarkers such as Cortisol, Melatonin, Glucose, Interleukin-1 beta (IL1-β), Glial fibrillary acidic protein (GFAP), and Brain-derived neurotrophic factor (BDNF). This ongoing research underscores EnLiSense's commitment to broadening the understanding and management of chronic diseases through continuous innovation. EnLiSense CCM is at the forefront of transforming chronic disease management. We welcome patients, clinicians, and investors to join us on this exciting journey towards a healthier future.

Learn more about EnLiSense

EnLiSense stands at the forefront of medical innovation, spearheading the development of advanced sweat sensor technology for real-time, non-invasive monitoring. Their offerings include both a first-of-its-kind device and an advanced data and AI platform, blending cutting-edge hardware with sophisticated analytics. Their flagship products, IBD Aware and Corti, are not just wearables; they are gateways to a new era in personalized healthcare. These devices cater to a wide range of use cases, profoundly resonating with both clinicians and patients. They facilitate proactive chronic disease management in conditions like inflammatory bowel disease (IBD) and stress-related disorders, offering clinicians and patients unprecedented insights into both physiological and disease states for treatment timing and effectiveness, symptom management, and dietary and lifestyle adjustments – aspects previously inaccessible in real-time. The technology is validated to continuously monitor a comprehensive range of biomarkers including Calprotectin, CRP, TNF-Alpha, IL-6, Cortisol, Melatonin, Glucose, and many others, transforming how healthcare professionals and patients approach treatment and management.

 

The journey of EnLiSense is characterized by a relentless pursuit of elevating the standard of care through continuous innovation. Their solutions are designed not only to meet current healthcare challenges but also to anticipate future needs. EnLiSense continues to expand research and development efforts into new biomarkers and disease applications, broadening the scope of the technology platform to encompass a wider spectrum of chronic conditions. This expansion is underpinned by a commitment to cost-effective, precision medicine, ensuring that each advancement brings us closer to a future where healthcare is more personalized, proactive, and patient-centered.

bottom of page